ClinVar Miner

Submissions for variant NM_000179.2(MSH6):c.3727A>T (p.Thr1243Ser) (rs147453999)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 16
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000588959 SCV000149328 likely benign not provided 2020-10-06 criteria provided, single submitter clinical testing In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 23047549, 23621914, 28687356, 26338694, 31159747)
Invitae RCV001081954 SCV000166233 likely benign Hereditary nonpolyposis colorectal neoplasms 2020-12-06 criteria provided, single submitter clinical testing
Ambry Genetics RCV000115419 SCV000186076 uncertain significance Hereditary cancer-predisposing syndrome 2020-03-28 criteria provided, single submitter clinical testing The p.T1243S variant (also known as c.3727A>T), located in coding exon 8 of the MSH6 gene, results from an A to T substitution at nucleotide position 3727. The threonine at codon 1243 is replaced by serine, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Illumina Clinical Services Laboratory,Illumina RCV000122966 SCV000430979 uncertain significance Lynch syndrome 2016-06-14 criteria provided, single submitter clinical testing
Color Health, Inc RCV000115419 SCV000685435 likely benign Hereditary cancer-predisposing syndrome 2020-03-16 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV001358662 SCV000695885 likely benign not specified 2021-03-22 criteria provided, single submitter clinical testing Variant summary: MSH6 c.3727A>T (p.Thr1243Ser) results in a conservative amino acid change located in the DNA mismatch repair protein MutS, C-terminal domain of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00027 in 251210 control chromosomes, predominantly at a frequency of 0.0011 within the South Asian subpopulation in the gnomAD database, including 1 homozygotes. The observed variant frequency within South Asian control individuals in the gnomAD database is approximately 7.7 fold of the estimated maximal expected allele frequency for a pathogenic variant in MSH6 causing Hereditary Nonpolyposis Colorectal Cancer phenotype (0.00014), strongly suggesting that the variant is a benign polymorphism found primarily in populations of South Asian origin. c.3727A>T has been reported in the literature in individuals with a variety of cancer types such as epithelial ovarian cancer (example, Pal_2012), kidney renal clear cell carcinoma in the TGCA cohort (Lu_2015), as a VUS in Malignant pleural mesothelioma (MPM) (example, Betti_2017), as a VUS in breast/ovarian cancer (example, Tsaousis_2019, Akcay_2020, Moradian_2021). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Nonpolyposis Colorectal Cancer. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Fifteen clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments (likely benign, n=3; VUS, n=12). Some submitters cite overlapping evidence utilized in the context of this evaluation. Based on the evidence outlined above, the variant was classified as likely benign.
Center for Human Genetics, Inc,Center for Human Genetics, Inc RCV000659895 SCV000781793 uncertain significance Hereditary nonpolyposis colorectal cancer type 5 2016-11-01 criteria provided, single submitter clinical testing
PreventionGenetics,PreventionGenetics RCV000588959 SCV000805896 uncertain significance not provided 2017-03-27 criteria provided, single submitter clinical testing
GeneKor MSA RCV000115419 SCV000822067 uncertain significance Hereditary cancer-predisposing syndrome 2018-08-01 criteria provided, single submitter clinical testing
Mendelics RCV000659895 SCV001135846 uncertain significance Hereditary nonpolyposis colorectal cancer type 5 2019-05-28 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000588959 SCV001469575 likely benign not provided 2020-03-03 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV001286961 SCV001473594 uncertain significance none provided 2019-10-24 criteria provided, single submitter clinical testing The MSH6 c.3727A>T; p.Thr1243Ser variant (rs147453999) is reported in the literature in individuals with hereditary cancer predisposition syndrome, ovarian cancer, or mesothelioma (Betti 2017, Pal 2012, Tsaousis 2019). This variant is also reported in ClinVar (Variation ID: 127589). It is found in the general South Asian population with an allele frequency of 0.1% (35/30614 alleles, including 1 homozygote) in the Genome Aggregation Database. The threonine at codon 1243 is highly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant may be deleterious. However, due to limited information, the clinical significance of this variant is uncertain at this time. REFERENCES Betti M et al. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. Cancer Lett. 2017 Oct 1;405:38-45. Pal T et al. Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer. Br J Cancer. 2012 Nov 6;107(10):1783-90. Tsaousis GN et al. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations. BMC Cancer. 2019 Jun 3;19(1):535.
CeGaT Praxis fuer Humangenetik Tuebingen RCV000588959 SCV001501271 uncertain significance not provided 2020-11-01 criteria provided, single submitter clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV000212687 SCV000592654 uncertain significance Carcinoma of colon no assertion criteria provided clinical testing The MSH6 p.Thr1243Ser variant was identified in 2 of 3972 proband chromosomes (frequency: 0.001) from individuals or families with malignant pleural mesothelioma, epithelial ovarian cancer (Betti 2017, Pal 2012). The variant was also identified in dbSNP (ID: rs147453999) as “With other allele”, in ClinVar (classified as uncertain significance by GeneDx, Ambry Genetics, Color Genomics; as likely benign by Invitae, IGLCA), Clinvitae, COGR, MutDB, and the Insight Hereditary Tumors Database. The variant was not identified in Cosmic, UMD-LSDB, Zhejiang Colon Cancer Database, or the Mismatch Repair Genes Variant Database. The variant was identified in control databases in 77 of 276950 chromosomes (1 homozygous) at a frequency of 0.0003 (Genome Aggregation Database Feb 27, 2017). It was observed in the following populations: “Other” in 7 of 6454 chromosomes (freq: 0.001), Latino in 21 of 34370 chromosomes (freq: 0.001), European in 14 of 126502 chromosomes (freq: 0.0001), and South Asian in 35 of 30782 chromosomes (freq: 0.001); it was not observed in the African, Ashkenazi Jewish, East Asian, or Finnish populations. The p.Thr1243 residue is conserved across mammals and other organisms, and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) suggest that the variant may impact the protein; however, this information is not predictive enough to assume pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In a study that integrated the prediction results of three in silico programs and two other structural properties, namely solvent accessibility and the change in the number of heavy atoms of amino acids in the MSH6 protein, the authors concluded the variant has an impact on the MSH6 protein (Terui 2013). In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.
True Health Diagnostics RCV000115419 SCV000788052 uncertain significance Hereditary cancer-predisposing syndrome 2017-09-27 no assertion criteria provided clinical testing
Center of Medical Genetics and Primary Health Care RCV001005027 SCV000987278 uncertain significance bilateral breast cancer 2020-04-08 no assertion criteria provided research ACMG Guidelines 2015 criteria PM1 Pathogenic Moderate: A domain mutATP5 (V1127-1321R aa) functioning in ATPase activity. Hot-spot has 30 non-VUS coding variants (19 pathogenic and 11 benign), pathogenicity = 63.3%, proximity score 9.180 > threshold 2.472. PP3 Pathogenic Supporting: 7 pathogenic predictions from DEOGEN2, FATHMM-MKL, M-CAP, MVP, MutationTaster, PrimateAI and SIFT vs 4 benign predictions from DANN, EIGEN, MutationAssessor and REVEL. BS1 Benign Strong: GnomAD exomes South Asian allele frequency = 0.00114 > 0.000649 derived from the 3,884 clinically reported variants in gene MSH6 of which 739 PATH, 2,198 VUS and 947 benign. BP1 Benign Supporting: 85 out of 114 non-VUS missense variants in gene MSH6 are BEN = 74.6% > threshold of 51.0%, and 947 out of 3,884 clinically reported variants in gene MSH6 are BEN = 24.4% > threshold of 24.0%. BP6: Multiple reputable databases/clinical laboratories cite the variant with conflicting classifications "uncertain significance" or "likely benign." Therefore, it has been classified as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.